HIV PRE-EXPOSURE PROPHYLAXIS
Clinical trials for HIV PRE-EXPOSURE PROPHYLAXIS explained in plain language.
Never miss a new study
Get alerted when new HIV PRE-EXPOSURE PROPHYLAXIS trials appear
Sign up with your email to follow new studies for HIV PRE-EXPOSURE PROPHYLAXIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Monthly HIV prevention pill could replace daily dosing
Prevention Recruiting nowThis study tests whether a new pill taken once a month (MK-8527) can prevent HIV-1 infection as well as the standard daily PrEP pill. About 4,390 adults at risk for HIV will participate. The goal is to find a more convenient prevention option that people can take less often.
Matched conditions: HIV PRE-EXPOSURE PROPHYLAXIS
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Prevention
Last updated May 17, 2026 07:04 UTC
-
Monthly HIV prevention pill could replace daily dosing for women
Prevention Recruiting nowThis study tests whether a new monthly pill (MK-8527) is better than the standard daily pill at preventing HIV infection in women. About 4,580 HIV-negative women who are sexually active will take either the monthly pill or a daily PrEP pill for comparison. Researchers will track …
Matched conditions: HIV PRE-EXPOSURE PROPHYLAXIS
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Prevention
Last updated May 17, 2026 06:51 UTC
-
New injectable PrEP study aims to boost HIV prevention in latine communities
Prevention Recruiting nowThis study tests a culturally-tailored program offering long-acting injectable PrEP (lenacapavir) to Latine gay, bisexual men and transgender women. The goal is to see if this community-delivered approach helps more people stay on PrEP compared to standard clinic care. Participan…
Matched conditions: HIV PRE-EXPOSURE PROPHYLAXIS
Phase: PHASE4 • Sponsor: Duke University • Aim: Prevention
Last updated May 08, 2026 12:03 UTC
-
Yearly HIV prevention shot could replace daily pills
Prevention Recruiting nowThis study tests a new way to prevent HIV using an injection given just once a year. The drug, lenacapavir, is given as a shot into the muscle. Researchers want to see if it is safe and how well it stays in the body over 12 months. About 350 people at risk for HIV will take part.
Matched conditions: HIV PRE-EXPOSURE PROPHYLAXIS
Phase: PHASE3 • Sponsor: Gilead Sciences • Aim: Prevention
Last updated Apr 28, 2026 13:02 UTC